Thank you for sharing!

Your article was successfully shared with the contacts you provided.

In January 2008, Jan Marini Skin Research suspended U.S. sales of its product, Age Intervention Eyelash Conditioner, which had been marketed as a cosmetic product that could be used to make eyelashes look longer and increase eyelash growth. The suspension came in the wake of a November 2007 seizure of approximately $2 million worth of the product by U.S. Marshals at the request of the U.S. Food and Drug Administration (“FDA”). According to the FDA, Age Intervention Eyelash Conditioner was an “unapproved and misbranded drug,” not a cosmetic. The product contained bimatoprost, an active ingredient in Lumigan®, an FDA-approved prescription drug for glaucoma that is manufactured by Allergan. (Allergan filed a related patent-infringement lawsuit against Jan Marini Skin Research in November 2007.) Eyelash growth is a reported side effect of Lumigan. See, Press Release, “Approximately $2 Million of Potentially Harmful ‘Cosmetic’ Eye Product Seized,” U.S. Food and Drug Administration, Nov. 16, 2007, available at www.fda.gov/bbs/topics/NEWS/2007/NEW01746.html; Rhonda L. Rundle, “Drug That Lengthens Eyelashes Sets Off Flutter,” The Wall Street Journal, Nov. 19, 2007, Page B1; Rhonda L. Rundle, “Jan Marini Eyelash Product Is Taken Off the U.S. Market,” The Wall Street Journal, Jan. 7, 2008, Page B7.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.